Skip to main content
SpringerLink
Log in

Zytokine

  • Chapter
Kompendium der praktischen Medizin

  • 13 Accesses

Zusammenfassung

Zytokine sind eine Gruppe potentiell antitumoraler Therapeutika. Zu ihnen gehören die Interferone (IFN), zu deren Wirkungsspektrum unter anderem eine direkter antiproliferativer Effekt auf maligne und normale Zellen zählt und die Gruppe der immunomodulatorischen Interleukine. Mit lnterleukin-2 (IL-2) hofft man, eine Immunantwort gegen Tumoren zu induzieren und therapeutisch nutzen zu können. Die antineoplastischen Wirkungen von IL-1, IL-2, IL-3, IL-4, IL-6, α-, ß- und γ-INF werden derzeit klinisch getestet. Ergebnisse, die den Einsatz außerhalb von kontrollierten Prüfungen rechtfertigen können, sind bisher jedoch nur von IFN und IL-2 publiziert worden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 35(8704):1509–1512

    Article  Google Scholar 

  2. Aulitzky WE, Aulitzky W, Eilerhorst J, Logothetis C, Gomahr A, Stöckle M, Thews O, Scheibenbogen C, Keilholz U, Huber C: Intermittend low dose IFN gamma for treatment of metastatic renal cell carcinoma: analysis of factors predicting clinical response and long term survival (submitted for publication)

    Google Scholar 

  3. Dillman RO, Church C, Oldham RK, West WH, Schwartzenberg L (1993) Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71:2358–2370

    Article  PubMed  CAS  Google Scholar 

  4. Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Poole M, Schnipper EF et al. (1986) Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. Am J Med 80:351–356

    Article  PubMed  CAS  Google Scholar 

  5. Fridrik MA (1993) Interferon-α beim Non-Hodgkin-Lymphom. Wien Med Wochenschr 143:429–434

    PubMed  CAS  Google Scholar 

  6. Gastl G, Aulitzky W, Tilg H, Thaler J, Berger M, Huber C (1990) Minimal interferon-alpha doses for hairy cell leukemia [letter; comment]. Blood 75:812–813

    PubMed  CAS  Google Scholar 

  7. Goldman CA, Skinnider LF, Maksymiuk AW (1993) Interferon instillation for malignant pleural effusions. Ann Oncol 4:141–145

    PubMed  CAS  Google Scholar 

  8. Hauschild A, Petres D (1992) Intralesional treatment of classical Kaposi sarcoma with interferon-alpha. Hautarzt 43:789–791

    PubMed  CAS  Google Scholar 

  9. Hehlmann R, Heimpel H, Griesshammer M, Kolb HJ, Heinze B, Hossfeld DK, Wickramanayake PD, Essers U, Thiele J, Georgii A et al. (1992) Chronic myelogenous leukemia: recent developments in prognostic evaluation and chemotherapy.The German CML Study Group. Leukemia 6:3

    Google Scholar 

  10. Heinzer H, Huland E, Huland H (1992) Adverse reaction to intravenous contrast media in patients treated with interleukin 2. Am J Roentgenol 158:1407

    CAS  Google Scholar 

  11. Kantarjian HM, Keatin MJ, Estey EH, O’Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M (1992) Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 10:772–778

    PubMed  CAS  Google Scholar 

  12. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alpha-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1984. J Clin Oncol 14:7–17

    PubMed  Google Scholar 

  13. Knobler R (1993) Interferon-α beim kutanen T-Zell-Lymphom. Wien Med Wochenschr 143:435–437

    PubMed  CAS  Google Scholar 

  14. Kuzel TM, Roenigk HJ, Rosen ST (1991) Mycosis fungoides and the Sezary syndrome: a review of pathogenesis, diagnosis, and therapy. J Clin Oncol 9:1298–1313

    PubMed  CAS  Google Scholar 

  15. Lee RE, Lotze MT, Skibber JM, Jucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7:7–20

    PubMed  CAS  Google Scholar 

  16. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Archili C, Vaghi M, Tancini G (1992) Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28:92–96

    Article  PubMed  CAS  Google Scholar 

  17. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher Rl, Weiss GR, Doroshow JH, Jaffe HS, Roper M et al. (1989) Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7:486–498

    PubMed  Google Scholar 

  18. McDonald RR, Georgouras K (1992) Treatment of basal cell carcinoma with intralesional interferon alpha: a case report and literature review. Australas J Dermatol 33:81–86

    Article  PubMed  CAS  Google Scholar 

  19. Mischke M (1993) Interferontherapie beim multiplen Myelom. Wien Med Wochenschr 143:425–428

    Google Scholar 

  20. Moertel CG, Rubin J, Kvols LK (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7:865–868

    PubMed  CAS  Google Scholar 

  21. Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B (1993) Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma 9:111–119

    Article  PubMed  CAS  Google Scholar 

  22. Oberg K, Alm G, Lindstrom H, Lundqvist G (1985) Successful treatment of therapy-resistant pancreatic cholera with human leucocyte interferon. Lancet 1 (8431):725–727

    Article  PubMed  CAS  Google Scholar 

  23. Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH, Parrillo JE (1988) Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750–754

    Article  PubMed  Google Scholar 

  24. Ozer H (1988) Biotherapy of chronic myelogenous leukemia with interferon. Semin Oncol 15:14

    PubMed  CAS  Google Scholar 

  25. Ravoud A, Bedane C, Geoffrois L, Lesimple T, Delaunay M (1999) Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Brit J Cancer 80:1679–1680

    Article  Google Scholar 

  26. Sagaster KP (1993) Interferon-α-Therapie beim Hypernephrom. Wien Med Wochenschr 143:443–447

    PubMed  CAS  Google Scholar 

  27. Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Lapporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, Coiffier B, Gisselbrecht C, for the groupe d’etude des lymphomes de l’adulte (1993) Recombinant interferon alpha-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608–1614

    Article  PubMed  CAS  Google Scholar 

  28. Studler G (1993) Lokoregionale Interferontherapie in der Urologie. Wien Med Wochenschr 143:448–450

    PubMed  CAS  Google Scholar 

  29. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1992) A prospective comparison of alpha-IFN and conventional chemotherapy in PH + chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. Haematologica 77:204–214

    Google Scholar 

  30. Whittington R, Faulds D (1993) A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446–514

    Article  PubMed  CAS  Google Scholar 

  31. Winkelhake JL, Gauny SS (1990) Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 42:1–28

    PubMed  CAS  Google Scholar 

  32. Wussow P von, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61:1071–1074

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Priv.-Doz. Dr. R. Kath MPH

    Present address: Klinik für Innere Medizin II (Onkologie, Hämatologie, Endokrinologie, Stoffwechselerkrankungen) der Friedrich-Schiller-Universität Jena, D-07740 Jena, Berlin, Deutschland

Authors and Affiliations

  1. Klinik für Innere Medizin II (Onkologie, Hämatologie, Endokrinologie, Stoffwechselerkrankungen) der Friedrich-Schiller-Universität Jena, D-07740 Jena, Berlin, Deutschland

    K. Höffken

  2. Abteilung für Hämatologie der III, Medizinischen Klinik der Universität Mainz, Deutschland

    W. Aulitzky

Authors
  1. Priv.-Doz. Dr. R. Kath MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Aulitzky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Höffken
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Arzt für Allgemeinmedizin, Arbeitsmedizin, Geburtshelfer, Prunkgasse 9, 55126, Mainz, Deutschland

    Benno König

  2. Kinderklinik der Universität München, Lindwurmstraße 4, 80337, München, Deutschland

    Dietrich Reinhardt

  3. Medizinische Klinik I Städtisches Krankenhaus Hildesheim, Lehrkrankenhaus der Medizinischen Hochschule Hannover, Weinberg 1, 31134, Hildesheim, Deutschland

    Hans-Peter Schuster

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kath, R., Aulitzky, W., Höffken, K. (2000). Zytokine. In: König, B., Reinhardt, D., Schuster, HP. (eds) Kompendium der praktischen Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59754-1_80

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59754-1_80

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64110-7

  • Online ISBN: 978-3-642-59754-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation